Increasing dopaminergic activity: Effects of L-dopa and bromocriptine on human sensory gating

Journal of Psychopharmacology

Volumn 18, Issue 3, 2004, Pages 388-394

  Oranje, B ^a   Gispen De Wied, C C ^b   Westenberg, H G M ^b   Kemner, C ^b   Verbaten, M N ^c   Kahn, R S ^b  

^a BISPEBJERG HOSPITAL   (Denmark)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Bromocriptine; L dopa; P50 suppression; Sensory gating

Indexed keywords

BROMOCRIPTINE; BROMOCRIPTINE MESILATE; CARBIDOPA; CARBIDOPA PLUS LEVODOPA; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; PLACEBO; PROTEIN P50;

AMPLITUDE MODULATION; ARTICLE; CHANNEL GATING; CONDITIONING; CONTROLLED STUDY; DIZZINESS; DOPAMINERGIC ACTIVITY; DRUG EFFECT; HUMAN; LITERATURE; MALE; NAUSEA; NEUROTRANSMISSION; NORMAL HUMAN; PRECURSOR; PRIORITY JOURNAL; PROVOCATION TEST; SENSORY SYSTEM; STIMULUS;

ACOUSTIC STIMULATION; ADULT; BRAIN; BROMOCRIPTINE; CROSS-OVER STUDIES; DOPAMINE AGENTS; DOPAMINE AGONISTS; DOUBLE-BLIND METHOD; ELECTROENCEPHALOGRAPHY; EVOKED POTENTIALS, AUDITORY; HOMOVANILLIC ACID; HUMANS; LEVODOPA; MALE; PROLACTIN; SENSORY DEPRIVATION; TIME FACTORS;

EID: 6044260209     PISSN: 02698811     EISSN: None     Source Type: Journal    
DOI: 10.1177/026988110401800310     Document Type: Article

References (39)

1. Abduljawad K A, Langley R W, Bradshaw C M, Szabadi E (1998) Effects of bromocriptine and haloperidol on prepulse inhibition of the acoustic startle response in man. J Psychopharmacol 12: 239-245
2. Abduljawad K A, Langley R W, Bradshaw C M, Szabadi E (1999) Effects of bromocriptine and haloperidol on prepulse inhibition: comparison of the acoustic startle eyeblink response and the N1/P2 auditory-evoked response in man. J Psychopharmacol 13: 3-9
3. Adler L E, Pachtman E, Franks R D, Pecevich M, Waldo M C, Freedman R (1982) Neurophysiological evidence for a defect in neuronal mechanisms involved in sensory gating in schizophrenia. Biol Psychiatry 17: 639-654
4. Andreasen N C, Flaum M, Arndt S (1992) The comprehensive assessment of symptoms and history (CASH): an instrument for assessing psychopathology and diagnosis. Arch Gen Psychiatry 49: 615-623
5. Braff D L, Geyer M A (1990) Sensorimotor gating and schizophrenia: human and animal model studies. Arch Gen Psychiatry 47: 181-188
6. Cadenhead K S, Light G A, Geyer M A, McDowell J E, Braff D L (2002) Neurobiological measures of schizotypal personality disorder: defining an inhibitory endophenotype? Am J Psychiatry 159: 869-871
7. Clementz B A, Geyer M A, Braff D L (1997) P50 suppression among schizophrenia and normal comparison subjects: a methodological analysis. Biol Psychiatry: 1035-1044
8. Clementz B A, Geyer M A, Braff D L (1998) Multiple site evaluation of P50 suppression among schizophrenia and normal comparison subjects. Schizophr Res 30: 71-80
9. Davis K L, Kahn R S, Ko G, Davidson M (1991) Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 148: 1474-1486
10. Dempski R E, Scholtz E C, Oberholtzer E R, Yeh K C (1989) Pharmaceutical design and development of a Sinemet controlled-release formulation. Neurology 39: 20-24
11. Drewe J, Mazer N, Abisch E, Krummen K, Keck M (1988) Differential effect of food on kinetics of bromocriptine in a modified release capsule and a conventional formulation. Eur J Clin Pharmacol 35: 535-541
12. Duncan G E, Sheitman B B, Lieberman J A (1999) An integrated view of pathophysiological models of schizophrenia. Brain Res Brain Res Rev 29: 250-264
13. Endicott J, Spitzer R L (1978) A diagnostic interview: the schedule for affective disorders and schizophrenia. Arch Gen Psychiatry 35:837-844
14. Frazer A E, Molinoff P B E, Winokur A E (1994) Biological bases of brain function and disease. Raven Press, New York
15. Freedman R, Waldo M C, Bickford-Wimer P C, Nagamoto H (1991) Elementary neuronal dysfunctions in schizophrenia. Schizophr Res 4: 233-243
16. Green M F (1998) Schizophrenia from a neurocognitive perspective: probing the impenetrable darkness. Allyn and Bacon, Inc., Boston, MA
17. Kahn R S, Davidson M (1995) Dopamine in schizophrenia. In den Boer J A, Westenberg H G M, van Praag H M (eds), Advances in the neurobiology of schizophrenia, pp. 204-220. Wiley & Sons Ltd, Chichester
18. Kenemans J L, Molenaar P C, Verbaten M N, Slangen J L (1991) Removal of the ocular artifact from the EEG: a comparison of time and frequency domain methods with simulated and real data. Psychophysiology 28: 114-121
19. Kopitar Z, Vrhovac B, Povsic L, Plavsic F, Francetic I, Urbancic J (1991) The effect of food and metoclopramide on the pharmacokinetics and side effects of bromocriptine. Eur J Drug Metab Pharmacokinet 16: 177-181
20. Kumari V, Soni W, Sharma T (1999) Normalization of information processing deficits in schizophrenia with closapine. Am J Psychiatry 156: 1046-1051
21. Kumari V, Soni W, Mathew V M, Sharma T (2000) Prepulse inhibition of the startle response in men with schizophrenia - effects of age of onset of illness, symptoms, and medication. Arch Gen Psychiatry 57:609-614
22. LeWitt P A, Nelson M V, Berchou R C, Galloway M P, Kesaree N, Kareti D, Schlick P (1989) Controlled-release carbidopa/levodopa (Sinemet 50/200 CR4): clinical and pharmacokinetic studies. Neurology 39: 45-53
23. Light G A, Malaspina D, Geyer M A, Luber B M, Coleman E A, Sackeim H A, Braff D L (1999) Amphetamine disrupts P50 suppression in normal subjects. Biol Psychiatry 46: 990-996
24. Light G A, Geyer M A, Clementz B A, Cadenhead K S, Braff D L (2000) Normal P50 suppression in schizophrenia patients treated with atypical antipsychotic medications. Am J Psychiatry 157: 767-771
25. McGhie A and Chapman J (1961) Disorders of attention and perception in early schizophrenia. Br J Med Psychol 34: 103-116
26. Munson P L, Mueller R A, Breese G R (1995) Principles of pharmacology, basic concepts and clinical applications. Chapman and Hall, New York,
27. Nagamoto H T, Adler L E, Waldo M C, Freedman R (1989) Sensory gating in schizophrenics and normal controls: effects of changing stimulation interval. Biol Psychiatry 25: 549-561
28. Nagamoto H T, Adler L E, Waldo M C, Griffith J (1991) Gating of auditory response in schizophrenics and normal control: effects of recording site and stimulation interval on the P50 wave. Schizophr Res 4: 31-40
29. Nelson M V, Berchou R C, Kareti D, LeWitt P A (1990) Pharmacokinetic evaluation of erythromycin and caffeine administered with bromocriptine. Clin Pharmacol Ther 47: 694-697
30. Oranje B, van Berckel B N, Kemner C, van Ree J M, Kahn R S, Verbaten M N (1999) P50 suppression and prepulse inhibition of the startle reflex in humans: a correlational study. Biol Psychiatry 45: 883-890
31. Oranje B, Gispen-de Wied C C, Verbaten M N, Kahn R S (2002a) Modulating sensory gating in healthy volunteers. The effects of ketamine and haloperidol. Biol Psychiatry 52: 887-895
32. Oranje B, Oel C J, Gispen-de Wied C C, Verbaten M N, Kahn R S (2002b) Effects of typical and atypical antipsychotics on the prepulse inhibition of the startle reflex in patients with schizophrenia. J Clin Psychopharmacol 4: 359-365
33. Schwarzkopf S B, Lamberti J S, Smith D A (1993) Concurrent assessment of acoustic startle and auditory P50 evoked potential measures of sensory inhibition. Biol Psychiatry 33: 815-828
34. Swerdlow N R, Eastvold A, Karban B, Ploum Y, Stephany N, Geyer M A, Cadenhead K, Auerbach P P (2002) Dopamine agonist effects on startle and sensorimotor gating in normal male subjects: time course studies. Psychopharmacology (Berl) 161: 189-201
35. Tandon R, Milner K, Jibson M D (1999) Antipsychotics from theory to practice: integrating clinical and basic data. J Clin Psychiatry 60 (Suppl 8): 21-28
36. Venables P H (1964) Input dysfunction in schizophrenia. In Maher B A (ed.), Progress in experimental personality research, pp. 1-47. Academic Press, New York
37. Ward P B, Hoffer L D, Liebert B J, Catts S V, O'Donnell M, Adler L E (1996) Replication of a P50 auditory gating deficit in Australian patients with schizophrenia. Psychiatry Res 64: 121-135
38. Yee C M, Nuechterlein K H, Morris S E, White P M (1998) P50 suppression in recent-onset schizophrenia: clinical correlates and risperidone effects. J Abnorm Psychol 107: 691-698
39. Yeh K C, August T F, Bush D F, Lasseter K C, Musson D G, Schwartz S, Smith M E, Titus D C (1989) Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies. Neurology 39: 25-38